Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
19.45
-0.05 (-0.26%)
At close: Dec 20, 2024, 4:00 PM
19.32
-0.13 (-0.67%)
After-hours: Dec 20, 2024, 4:24 PM EST
Arrowhead Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | 2019 - 2015 |
| Revenue | 3.55 | 3.55 | 240.74 | 243.23 | 138.29 | 87.99 | Upgrade
|
| Revenue Growth (YoY) | -98.52% | -98.52% | -1.03% | 75.89% | 57.16% | -47.87% | Upgrade
|
| Gross Profit | 3.55 | 3.55 | 240.74 | 243.23 | 138.29 | 87.99 | Upgrade
|
| Selling, General & Admin | 124.54 | 124.54 | 108.82 | 132.44 | 85.44 | 54 | Upgrade
|
| Research & Development | 480.09 | 480.09 | 336.92 | 289.3 | 201.88 | 127.15 | Upgrade
|
| Operating Expenses | 604.63 | 604.63 | 445.74 | 421.74 | 287.32 | 181.15 | Upgrade
|
| Operating Income | -601.08 | -601.08 | -205 | -178.51 | -149.04 | -93.16 | Upgrade
|
| Interest Expense | -32.35 | -32.35 | -18.33 | - | - | - | Upgrade
|
| Interest & Investment Income | 22.72 | 22.72 | 15.3 | 5.03 | 6.12 | 9.19 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.75 | -1.75 | 1.54 | 0.77 | 2.07 | -0.6 | Upgrade
|
| EBT Excluding Unusual Items | -612.46 | -612.46 | -206.49 | -172.71 | -140.85 | -84.57 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.02 | Upgrade
|
| Pretax Income | -612.46 | -612.46 | -206.49 | -172.71 | -140.85 | -84.55 | Upgrade
|
| Income Tax Expense | -2.77 | -2.77 | 2.78 | 3.79 | 0 | 0 | Upgrade
|
| Earnings From Continuing Operations | -609.69 | -609.69 | -209.28 | -176.49 | -140.85 | -84.55 | Upgrade
|
| Minority Interest in Earnings | 10.2 | 10.2 | 4 | 0.43 | - | - | Upgrade
|
| Net Income | -599.49 | -599.49 | -205.28 | -176.06 | -140.85 | -84.55 | Upgrade
|
| Net Income to Common | -599.49 | -599.49 | -205.28 | -176.06 | -140.85 | -84.55 | Upgrade
|
| Shares Outstanding (Basic) | 120 | 120 | 107 | 105 | 104 | 101 | Upgrade
|
| Shares Outstanding (Diluted) | 120 | 120 | 107 | 105 | 104 | 101 | Upgrade
|
| Shares Change (YoY) | 12.21% | 12.21% | 1.26% | 1.62% | 3.00% | 2.14% | Upgrade
|
| EPS (Basic) | -5.00 | -5.00 | -1.92 | -1.67 | -1.36 | -0.84 | Upgrade
|
| EPS (Diluted) | -5.00 | -5.00 | -1.92 | -1.67 | -1.36 | -0.84 | Upgrade
|
| Free Cash Flow | -604.32 | -604.32 | -330.63 | -188.91 | 147.75 | -107.75 | Upgrade
|
| Free Cash Flow Per Share | -5.05 | -5.05 | -3.10 | -1.79 | 1.42 | -1.07 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -16927.06% | -16927.06% | -85.16% | -73.39% | -107.77% | -105.87% | Upgrade
|
| Profit Margin | -16882.37% | -16882.37% | -85.27% | -72.39% | -101.85% | -96.09% | Upgrade
|
| Free Cash Flow Margin | -17018.30% | -17018.30% | -137.34% | -77.67% | 106.84% | -122.46% | Upgrade
|
| EBITDA | -582.49 | -582.49 | -192.51 | -168.09 | -140.77 | -87.22 | Upgrade
|
| EBITDA Margin | - | - | -79.97% | -69.11% | -101.79% | -99.12% | Upgrade
|
| D&A For EBITDA | 18.6 | 18.6 | 12.49 | 10.42 | 8.27 | 5.94 | Upgrade
|
| EBIT | -601.08 | -601.08 | -205 | -178.51 | -149.04 | -93.16 | Upgrade
|
| EBIT Margin | - | - | -85.16% | -73.39% | -107.77% | -105.87% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.